{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:32:43Z","timestamp":1792647163977,"version":"4.5.0"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T00:00:00Z","timestamp":1315353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0024265","type":"journal-article","created":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T20:48:32Z","timestamp":1315428512000},"page":"e24265","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":34,"title":["Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization"],"prefix":"10.1371","volume":"6","author":[{"given":"Eva","family":"Jager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent H. J.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen G.","family":"te Marvelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvia","family":"Agur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Vainstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,9,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","article-title":"CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.","volume":"19","author":"ML Linenberger","year":"2005","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood.V97.10.3197","article-title":"Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.","volume":"97","author":"VH van Der Velden","year":"2001","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.","volume":"104","author":"RA Larson","year":"2005","journal-title":"Cancer"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.13.13","article-title":"The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in MRC AML15 trial.","volume":"108","author":"AK Burnett","year":"2006","journal-title":"Blood"},{"key":"ref5","first-page":"657","article-title":"Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia\u2013ongoing trials.","volume":"30","author":"B Gleissner","year":"2007","journal-title":"Onkologie"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1177\/00912700122012751","article-title":"Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.","volume":"41","author":"JA Dowell","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics.","volume":"93","author":"ED Lobo","year":"2004","journal-title":"J Pharm Sci"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0006-3495(03)74516-0","article-title":"An integrated model of epidermal growth factor receptor trafficking and signal transduction.","volume":"85","author":"H Resat","year":"2003","journal-title":"Biophys J"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0169-409X(96)00013-0","article-title":"Importance of receptor-mediated endocytosis in peptide dekivery and targeting: kinetic aspects.","volume":"19","author":"H Sato","year":"1996","journal-title":"Adv Drug Del Rev"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jtbi.2004.03.009","article-title":"Analysis of compartmental models of ligand-induced endocytosis.","volume":"229","author":"AR Tzafriri","year":"2004","journal-title":"J Theor Biol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0092-8674(81)90061-1","article-title":"A steady state model for analyzing the cellular binding, internalization and degradation of polypeptide ligands.","volume":"25","author":"HS Wiley","year":"1981","journal-title":"Cell"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","article-title":"General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.","volume":"28","author":"DE Mager","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s11095-005-5642-4","article-title":"Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.","volume":"22","author":"CM Ng","year":"2005","journal-title":"Pharm Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11095-005-8814-3","article-title":"Pharmacokinetics\/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers.","volume":"23","author":"CM Ng","year":"2006","journal-title":"Pharm Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.leu.2403350","article-title":"High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.","volume":"18","author":"VH van der Velden","year":"2004","journal-title":"Leukemia"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2006-09-047399","article-title":"CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.","volume":"109","author":"RB Walter","year":"2007","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.leu.2403205","article-title":"Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.","volume":"18","author":"I Jedema","year":"2004","journal-title":"Leukemia"},{"key":"ref18","article-title":"Phase II-III Study of Gemtuzumab Ozogamicin Monotherapy versus Best Supportive Care in Older Patients with Newly Diagnosed AML Unfit for Intensive Chemotherapy: First Results of the EORTC-GIMEMA AML-19 Trial","author":"A Sergio","year":"2008"},{"key":"ref19"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood.V59.2.216.216","article-title":"Bone marrow cell count per cubic millimeter bone marrow: a new parameter for quantitating therapy-induced cytoreduction in acute leukemia.","volume":"59","author":"W Hiddemann","year":"1982","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1038\/sj.onc.1210364","article-title":"The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.","volume":"26","author":"L Pagano","year":"2007","journal-title":"Oncogene"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood-2004-07-2784","article-title":"Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.","volume":"105","author":"RB Walter","year":"2005","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.","volume":"93","author":"EL Sievers","year":"1999","journal-title":"Blood"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0024265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T09:14:35Z","timestamp":1592903675000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0024265"}},"subtitle":[],"editor":[{"given":"Robert","family":"Planque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,9,7]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0024265","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,7]]}}}